New partnership: Xilaplus® AF in Turkey
Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey.
Gastroenterology
8
Congresses: Noventure participates at NeuroGASTRO 2017, Cork, Ireland, with an innovative approach to IBS
Noventure, as part of its continued commitment to Gastroenterology, participated at the recent NeuroGASTRO 2017 meeting, which brought together leading experts and young investigators in neurogastroenterology, digestive motility and functional gastrointestinal diseases from Europe and from all around the world.
The new product Gelsectan® was depicted at the Noventure´s stand as a teaser campaign, under the motto “Mucoprotection”.
Gelsectan® Launched In Spain
We are pleased to announce the launch of our new IBS product Gelsectan® in its first market, Spain. The product is distributed by Norgine, as part of an agreement signed last March: http://noventure.com/corporate-press-release-norgine-and-noventure-enter-agreement-commercialize-gelsectanr-spain
